	US 12,486,514 B2
	Method to specifically stimulate survival and expansion of genetically-modified immune cells
Natasha Vinanica, Singapore (SG); Arthur Yong, Singapore (SG); Dario Campana, Singapore (SG); and Masaru Imamura, Niigata (JP)
Assigned to National University of Singapore, Singapore (SG)
Appl. No. 17/267,617
Filed by National University of Singapore, Singapore (SG)
PCT Filed Aug. 27, 2019, PCT No. PCT/IB2019/057217 § 371(c)(1), (2) Date Feb. 10, 2021, PCT Pub. No. WO2020/044239, PCT Pub. Date Mar. 5, 2020.
Claims priority of provisional application 62/724,488, filed on Aug. 29, 2018.
Prior Publication US 2021/0324388 A1, Oct. 21, 2021
Int. Cl. C12N 15/62 (2006.01); A61K 38/00 (2006.01); A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/42 (2025.01); A61P 35/02 (2006.01); C07K 14/72 (2006.01); C07K 14/725 (2006.01); C07K 16/28 (2006.01); C12N 5/0783 (2010.01); C12N 15/85 (2006.01)

CPC C12N 15/625 (2013.01) [A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/4201 (2025.01); A61K 40/4211 (2025.01); A61P 35/02 (2018.01); C07K 14/7051 (2013.01); C07K 14/72 (2013.01); C07K 16/2803 (2013.01); C12N 5/0636 (2013.01); C12N 15/85 (2013.01); A61K 38/00 (2013.01); A61K 2239/31 (2023.05); A61K 2239/38 (2023.05); A61K 2239/48 (2023.05)]

12 Claims

1. A mammalian T cell comprising a vector, the vector comprising a nucleic acid encoding:

a) an erythropoietin (Epo) receptor;

b) a 2A peptide; and

c) a chimeric antigen receptor comprising:

i) a signal peptide;

ii an extracellular receptor domain that binds CD19;

iii) a hinge and transmembrane domain that anchors the extracellular receptor domain on the surface of a cell; and

iv) an effector domain;

wherein the Epo receptor is expressed on the mammalian T cell surface, and

wherein the nucleic acid encodes SEQ ID NO: 12.